oPatientPlus articles are written by UK doctors and are based on research evidence, UK and European Guidelines. They are designed for health professionals to use, so you may find the language more technical than the condition leaflets.
There is no difference between mushrooms and toadstools, although the term toadstools has gradually become applied to toxic types. They are all agarics (ie fungi with gills beneath the cap).
Mushrooms found in gardens or on lawns are highly unlikely to be seriously toxic but may cause gastrointestinal upsets or be hallucinogenic.
- Poisoning with potentially lethal mushrooms in the UK is extremely rare.
- Highly toxic types are not likely to be found in towns or cities.
- Amanita phalloides (death cap) is the most toxic UK species and is found in all areas with the possible exception of Sutherland and Western Ross. The equally toxic Amanita virosa is found in the birch woods of the north.
- Cortinarius spp. are becoming more frequent but only three cases of poisoning have been reported in Britain. Symptoms may not start until several days after ingestion.
- Mushrooms which cause features within 6 hours of ingestion are unlikely to be seriously toxic.
- A long latency period (>6 hours), seen in a small number of cases (estimated at about 2% in one series), can be observed with amatoxins, orellanus, and gyromitrin syndromes. This generally signifies a serious ingestion and should be considered potentially life-threatening.
- Gastrointestinal disturbance nearly always occurs, eg nausea, vomiting, abdominal pain.
- Other symptoms include blurred vision, headache, loss of consciousness and confusion.
- In severe cases there may be features of organ failure, eg jaundice, haemorrhage.
- Food poisoning.
- Other intoxications, including illicit or prescription drugs.
- Other causes of acute renal failure.
- Other causes of liver failure.
- Psychosomatic: some patients have been reported to develop anxiety-related symptoms after learning that they have eaten wild mushrooms.
- Further investigations will be dependent on the clinical features and wellbeing of the patient and identification of the ingested mushroom.
- Urinary amanitin analysis is a valuable diagnostic tool.
See separate article Acute Poisoning - General Measures.
- Pre-hospital: make every attempt to identify the ingested mushroom. TOXBASE® has descriptions and photographs to help with identification. Care is otherwise supportive.
- Early onset of gastrointestinal symptoms predicts a benign course so nothing more than symptom control may be warranted.
- Consider activated charcoal in those presenting with gastrointestinal symptoms 6 hours after ingestion or if a patient presents before symptom development following known ingestion of hepatotoxic or nephrotoxic species.
- There is evidence to suggest that multi-dose activated charcoal may be more beneficial in amanita poisonings, as some of the toxins undergo enterohepatic circulation.
- Contact regional UK National Poisons Information Centre (Tel: 0844 892 0111).
- Observe for 6 hours to exclude central nervous system (CNS) and gastrointestinal toxicity. Treat symptomatically.
- Atropine for cholinergic symptoms (eg as with inocybe mushroom toxicity) and pyridoxine for gyromitra (see below).
- The very rare hepatotoxic mushrooms can cause gastrointestinal symptoms from 6 hours onwards.
- N-acetylcysteine is also used as an antidote for hepatotoxicity associated with mushroom poisoning.
- Consult specific entries in TOXBASE® if the mushroom has been identified.
Specific mushroom toxicities
- The most poisonous mushroom toxins are produced by A. phalloides.
- The main toxins responsible are the amatoxins. The amatoxins cause necrosis of the liver and, to a lesser degree, the kidney.
- Poisoning is characterised by a delay of between 6 and 24 hours in the onset of symptoms following ingestion. Violent vomiting, diarrhoea, and abdominal pain are the first symptoms. Patients then make an apparent recovery, but this is followed a few days later by hepatic and renal failure.
- Therapy includes:
- Supportive care, including correction of hypoglycaemia and electrolyte imbalance.
- Gastric lavage and activated charcoal.
- Anecdotal and animal studies suggest a potential benefit of high-dose penicillin, silibinin (a constituent of the extract silymarin derived from the milk thistle, Silybum marianum), cimetidine, aucubin (an iridoid glycoside of Aucuba japonica) and kutkin.
- Fulminant hepatic failure may require a liver transplant.
- Factors associated with a poor prognosis are low blood pressure, encephalopathy, mucosal haemorrhage, oliguria, hypoglycaemia, thrombocytopenia, hyponatraemia, raised urea, hepatic failure with raised international normalised ratio, and raised activated partial thromboplastin time values.
- Orellanine is a nephrotoxin found in some Cortinarius spp.
- Early symptoms are often vague, with gastrointestinal dysfunction 1-2 days after ingestion, and so poisoning may initially be overlooked.
- Patients often first present with acute renal failure which may follow at any time from 36 hours to 2 weeks after ingestion. Supportive care is the only therapeutic option.
- No specific treatment is available and therapy is directed toward the renal failure, including dialysis and possible transplantation.
- Common names: common white fibre head, peaked inocybe, red-staining inocybe, straw-coloured fibre head, turnip foot inocybe, white fibre head, woolly inocybe.
- There are over eighty recognised Inocybe species found in the UK and Ireland. Differentiation between different fungi within the genus is very difficult.
- Some inocybe mushrooms contain muscarine.
- Features develop between 15 minutes and 2 hours of ingestion and include perspiration, salivation, lacrimation, vomiting, abdominal pain, diarrhoea, urgency of micturition, flushing, bradycardia, hypotension, constricted pupils and blurred vision.
- Deaths are uncommon.
- This is a nonspecific term for fungi which are hallucinogenic.
- In the UK they are commonly liberty cap mushrooms (Psilocybe semilanceata), which are often found in parks, golf courses and football pitches.
- The fatal dose is not known and potency is variable.
- Hallucinogenic effects occur after ingestion of 20-100 mushrooms. Signs of intoxication generally develop within 1 hour and may persist for up to 15 hours.
- Features include nausea, vomiting, abdominal pain, flushing of the face and neck, tachycardia, dilated pupils, diastolic hypertension and drowsiness.
- Rhabdomyolysis leading to renal failure, arrhythmias and myocardial infarction have been reported.
- Behavioural effects vary from restless overactivity with lack of co-operation, and aggressiveness, to withdrawn, uncommunicative staring.
- Perceptual abnormalities include visual hallucinations, distorted body image, sounds and tactile sensation.
- Ability to judge heights and distances may be grossly impaired.
- All symptomatic patients should be referred to hospital.
- Activated charcoal (50 g for adults; 1 g/kg for children) only if the patient presents within 1 hour of ingestion.
- Observe for at least 4 hours after ingestion. Monitor pulse, temperature, blood pressure, cardiac rhythm and perform a 12-lead ECG.
- Check renal function, electrolytes and creatine kinase in symptomatic patients.
- Sedate if necessary with intravenous lorazepam or diazepam.
- Frequent or prolonged seizures should be treated with intravenous diazepam or lorazepam.
Other mushroom toxicities
- Gastrointestinal mushroom syndromes present with abdominal discomfort, cramping, nausea, vomiting, and/or diarrhoea. Dehydration is the most common complication. Most symptoms resolve by 24 hours and the prognosis is generally good.
- Anticholinergic symptoms can occur: dizziness, lack of co-ordination, ataxia, seizures, hallucinations, muscle spasms, flushing, and dilated pupils may be observed.
- Cholinergic effects may result from muscarine ingestion: salivation, bladder cramping, diarrhoea and difficulty with visual accommodation.
- Neuropsychiatric symptoms: include hallucinations or delirium. Muscle weakness, drowsiness, hallucinations, hyperkinesis, and mydriasis have been described. Patients may have hallucinations while awake and then have a prolonged sleep that lasts hours. The prognosis is generally good and symptoms resolve within 24 hours.
- The Coprinus syndrome: rapid onset of nausea, vomiting, tachycardia, palpitations, paraesthesias, diaphoresis, and flushing. Hypotension may also occur. This syndrome has been referred to as a disulfiram-like reaction, as it is associated with ethanol use from 30 minutes to 5 days following a mushroom meal. Symptoms generally last 2-4 hours.
- Gyromitrin toxicity may manifest at 4-6 hours post-ingestion with gastrointestinal dysfunction. Dehydration, hepatic dysfunction, methaemoglobinaemia, intravascular haemolysis and cental nervous system effects (eg malaise, tremor, myoclonus, delirium, seizures, encephalopathy) may occur.
- Respiratory: aspiration pneumonia, non-cardiogenic pulmonary oedema.
- CNS complications: convulsions are common in gyromitrin poisoning, but they also may be due to hypoxia, acidosis, and metabolic abnormalities. Cerebral oedema may be a complication of hypoxia, acidosis and hepatic failure.
- Hepatic complications: liver failure and hypoglycaemia are complications for amatoxin and gyromitrin poisoning.
- Renal failure is a common complication of orellanine poisoning but also may be due to hypoperfusion and shock and may be part of the hepatorenal syndrome.
- Methaemoglobinaemia and haemolysis may complicate gyromitrin poisoning.
- Trauma may complicate hallucinogenic mushroom poisoning.
- Hypovolaemia and electrolyte disturbances may complicate any mushroom poisoning.
- The prognosis in the great majority of cases of mushroom poisoning is excellent.
- Amatoxin poisoning: with good supportive care, the mortality rate for amatoxin poisoning may be reduced from 60% but, owing to progressing fulminant hepatic failure, is still high (5-20%).
- Gyromitrin poisoning: most recover and death is rare.
- Orellanine poisoning: a shorter time course between ingestion and toxicity correlates with a worse prognosis. Mortality is high but mild renal insufficiency may resolve within months of the ingestion.
- Don't take any risks with wild mushrooms and keep children well away.
- Education: even experienced mycologists may not be able to distinguish edible from poisonous mushrooms without microscopic examination.
- Identifying mushrooms is an exact science that is very difficult and time-consuming.
- Gourmet cooks who have harvested wild mushrooms have been poisoned. To be safe, avoid all wild mushrooms.
Further reading & references
- Toxbase®; (Registration is free for doctors who are employed by an NHS practice.)
- Eren SH, Demirel Y, Ugurlu S, et al; Mushroom poisoning: retrospective analysis of 294 cases. Clinics (Sao Paulo). 2010 May;65(5):491-6.
- Butera R, Locatelli C, Coccini T, et al; Diagnostic accuracy of urinary amanitin in suspected mushroom poisoning: a pilot study. J Toxicol Clin Toxicol. 2004;42(6):901-12.
- Giannini L, Vannacci A, Missanelli A, et al; Amatoxin poisoning: a 15-year retrospective analysis and follow-up evaluation of Clin Toxicol (Phila). 2007 Jun-Aug;45(5):539-42.
- Magdalan J, Ostrowska A, Piotrowska A, et al; Benzylpenicillin, acetylcysteine and silibinin as antidotes in human hepatocytes Exp Toxicol Pathol. 2010 Jul;62(4):367-73. Epub 2009 Jun 24.
- Magdalan J, Piotrowska A, Gomulkiewicz A, et al; Influence of commonly used clinical antidotes on antioxidant systems in human Hum Exp Toxicol. 2011 Jan;30(1):38-43. Epub 2010 Apr 8.
- Vetter J; Toxins of Amanita phalloides. Toxicon. 1998 Jan;36(1):13-24.
- Riordan M, Rylance G, Berry K; Poisoning in children 4: household products, plants, and mushrooms. Arch Dis Child. 2002 Nov;87(5):403-6.
- Habal R et al; Mushroom Toxicity, Medscape, Apr 2011
- Burton JR Jr, Ryan C, Shaw-Stiffel TA; Liver transplantation in mushroom poisoning. J Clin Gastroenterol. 2002 Sep;35(3):276-80.
- Trabulus S, Altiparmak MR; Clinical features and outcome of patients with amatoxin-containing mushroom Clin Toxicol (Phila). 2011 Apr;49(4):303-10.
- Karlson-Stiber C, Persson H; Cytotoxic fungi--an overview. Toxicon. 2003 Sep 15;42(4):339-49.
- Svendsen BS, Gjellestad A, Eivindson G, et al; Serious mushroom poisoning by Cortinarius and Amanita virosa. Tidsskr Nor Laegeforen. 2002 Mar 20;122(8):777-80.
- Stallard D, Edes TE; Muscarinic poisoning from medications and mushrooms. A puzzling symptom complex. Postgrad Med. 1989 Jan;85(1):341-5.
- Koppel C; Clinical symptomatology and management of mushroom poisoning. Toxicon. 1993 Dec;31(12):1513-40.
Disclaimer: This article is for information only and should not be used for the diagnosis or treatment of medical conditions. EMIS has used all reasonable care in compiling the information but make no warranty as to its accuracy. Consult a doctor or other health care professional for diagnosis and treatment of medical conditions. For details see our conditions.
|Original Author: Dr Colin Tidy||Current Version: Dr Gurvinder Rull||Peer Reviewer: Dr Adrian Bonsall|
|Last Checked: 19/08/2011||Document ID: 2478 Version: 22||© EMIS|